NCT05989204View on ClinicalTrials.gov

TmCD19-IL18 in CD19+ Cancers

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 13, 2023

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2041

Conditions
Non Hodgkin Lymphoma
Interventions
BIOLOGICAL

TmCD19-IL18

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

Trial Locations (1)

19104

RECRUITING

University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

Kite, A Gilead Company

INDUSTRY

lead

University of Pennsylvania

OTHER